Protara Therapeutics assumed with a Buy, $22 target at Guggenheim

As previously reported, Guggenheim assumed coverage of Protara Therapeutics with a Buy rating and $22 price target. The clinical-stage biotech company is currently trading at about a $30M diluted market-cap, or roughly $50M enterprise value, with cash runway into 2025, notes the analyst. Lead asset TARA-002 is in development for the “large opportunity” of non-muscle invasive bladder cancer, or NMIBC, as well as rare disease lymphatic malformations, the firm tells investors.